234 related articles for article (PubMed ID: 26872388)
1. Effect of Ethanol on the Metabolic Characteristics of HIV-1 Integrase Inhibitor Elvitegravir and Elvitegravir/Cobicistat with CYP3A: An Analysis Using a Newly Developed LC-MS/MS Method.
Midde NM; Rahman MA; Rathi C; Li J; Meibohm B; Li W; Kumar S
PLoS One; 2016; 11(2):e0149225. PubMed ID: 26872388
[TBL] [Abstract][Full Text] [Related]
2. Alterations in cellular pharmacokinetics and pharmacodynamics of elvitegravir in response to ethanol exposure in HIV-1 infected monocytic (U1) cells.
Midde NM; Sinha N; Lukka PB; Meibohm B; Kumar S
PLoS One; 2017; 12(2):e0172628. PubMed ID: 28231276
[TBL] [Abstract][Full Text] [Related]
3. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
DeJesus E; Rockstroh JK; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Yale K; Szwarcberg J; White K; Cheng AK; Kearney BP;
Lancet; 2012 Jun; 379(9835):2429-2438. PubMed ID: 22748590
[TBL] [Abstract][Full Text] [Related]
4. Elvitegravir concentrations in seminal plasma in HIV-1-infected men.
Imaz A; Niubó J; Kashuba AD; Ferrer E; Sykes C; Rozas N; Acerete L; Vila A; Podzamczer D
HIV Med; 2017 Mar; 18(3):225-230. PubMed ID: 27477062
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and safety of boosted elvitegravir in subjects with hepatic impairment.
Custodio JM; Rhee M; Shen G; Ling KH; Kearney BP; Ramanathan S
Antimicrob Agents Chemother; 2014 May; 58(5):2564-9. PubMed ID: 24550332
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects.
Ramanathan S; Custodio JM; Wei X; Wang H; Fordyce M; Dave A; Ling KH; Szwarcberg J; Kearney BP
J Acquir Immune Defic Syndr; 2016 Jul; 72(3):281-8. PubMed ID: 26885802
[TBL] [Abstract][Full Text] [Related]
7. A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients.
Aouri M; Calmy A; Hirschel B; Telenti A; Buclin T; Cavassini M; Rauch A; Decosterd LA
J Mass Spectrom; 2013 May; 48(5):616-25. PubMed ID: 23674286
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetics of Boosted-Elvitegravir in HIV-Infected Patients.
Custodio JM; Gordi T; Zhong L; Ling KH; Ramanathan S
J Clin Pharmacol; 2016 Jun; 56(6):723-32. PubMed ID: 26449283
[TBL] [Abstract][Full Text] [Related]
9. Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.
Imaz A; Podzamczer D
Expert Rev Anti Infect Ther; 2017 Mar; 15(3):195-209. PubMed ID: 28117606
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a LC-MS/MS method for the in vitro analysis of 1-hydroxymidazolam in human liver microsomes: application for determining CYP3A4 inhibition in complex matrix mixtures.
Mooiman KD; Maas-Bakker RF; Rosing H; Beijnen JH; Schellens JH; Meijerman I
Biomed Chromatogr; 2013 Sep; 27(9):1107-16. PubMed ID: 23674377
[TBL] [Abstract][Full Text] [Related]
11. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP
AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057
[TBL] [Abstract][Full Text] [Related]
12. Influence of Ethanol on Darunavir Hepatic Clearance and Intracellular PK/PD in HIV-Infected Monocytes, and CYP3A4-Darunavir Interactions Using Inhibition and in Silico Binding Studies.
Midde NM; Gong Y; Cory TJ; Li J; Meibohm B; Li W; Kumar S
Pharm Res; 2017 Sep; 34(9):1925-1933. PubMed ID: 28616684
[TBL] [Abstract][Full Text] [Related]
13. Co-administration of elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine and atazanavir in treatment-experienced HIV patients.
Biagi M; Badowski ME; Chiampas T; Young J; Patel M; Vaughn P
Int J STD AIDS; 2017 Jul; 28(8):766-772. PubMed ID: 27587601
[TBL] [Abstract][Full Text] [Related]
14. Biotransformation of Cobicistat: Metabolic Pathways and Enzymes.
Wang P; Shehu AI; Liu K; Lu J; Ma X
Drug Metab Lett; 2016; 10(2):111-23. PubMed ID: 26935921
[TBL] [Abstract][Full Text] [Related]
15. Elvitegravir: a once-daily inhibitor of HIV-1 integrase.
Wills T; Vega V
Expert Opin Investig Drugs; 2012 Mar; 21(3):395-401. PubMed ID: 22321026
[TBL] [Abstract][Full Text] [Related]
16. The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment.
Bruce RD; Winkle P; Custodio JM; Wei LX; Rhee MS; Kearney BP; Ramanathan S; Friedland GH
J Acquir Immune Defic Syndr; 2013 Aug; 63(4):480-4. PubMed ID: 23599011
[TBL] [Abstract][Full Text] [Related]
17. Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF.
Schrijvers R; Debyser Z
Expert Opin Pharmacother; 2012 Sep; 13(13):1969-83. PubMed ID: 22849516
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and bioequivalence evaluation of single-tablet and separate-tablet regimens for once-daily cobicistat-boosted elvitegravir in healthy Japanese male subjects: A randomized, two-way crossover study.
Shiomi M; Matsuki S; Ikeda A; Ishikawa T; Nishino N; Kimura M; Kumagai Y; Irie S
Clin Pharmacol Drug Dev; 2015; 4(3):218-25. PubMed ID: 27140802
[TBL] [Abstract][Full Text] [Related]
19. HIV-2 antiviral potency and selection of drug resistance mutations by the integrase strand transfer inhibitor elvitegravir and NRTIs emtricitabine and tenofovir in vitro.
Andreatta K; Miller MD; White KL
J Acquir Immune Defic Syndr; 2013 Apr; 62(4):367-74. PubMed ID: 23187937
[TBL] [Abstract][Full Text] [Related]
20. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients.
Kulkarni R; Abram ME; McColl DJ; Barnes T; Fordyce MW; Szwarcberg J; Cheng AK; Miller MD; White KL
HIV Clin Trials; 2014; 15(5):218-30. PubMed ID: 25350960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]